• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant
EMBO Mol Med. 2022 Feb 8:e15298. doi: 10.15252/emmm.202115298. Online ahead of print.ABSTRACTThe emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants has altered the trajectory of the COVID-19 pandemic and raised some uncertainty on long term efficiency of vaccine strategy. The development of new therapeutics against a wide range of SARS-CoV-2 variants is imperative. We here have designed an inhalable siRNA, C6G25S, which covers 99.8% of current SARS-CoV-2 variants and is capable of inhibiting dominant strains, including Alpha, Delta, Gamma and Epsilon, at picomolar ranges of IC50 in vitro. Mo...
Source: Molecular Medicine - February 9, 2022 Category: Molecular Biology Authors: Yi-Chung Chang Chi-Fan Yang Yi-Fen Chen Chia-Chun Yang Yuan-Lin Chou Hung-Wen Chou Tein-Yao Chang Tai-Ling Chao Shu-Chen Hsu Si-Man Ieong Ya-Min Tsai Ping-Cheng Liu Yuan-Fan Chin Jun-Tung Fang Han-Chieh Kao Hsuan-Ying Lu Jia-Yu Chang Ren-Shiuan Weng Qian- Source Type: research